Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Azithromycin

To Patients

To Patients

Therapeutic Approach

Anti-Infective

Azithromycin is an oral antibiotic with anti-inflammatory properties.

Status

A Phase 3 trial showed CF patients with chronic Pseudomonas aeruginosa who took azithromycin experienced improved lung function and weight gain and decreased hospitalization rate. A follow-up trial showed that azithromycin decreased exacerbations in younger people with CF not infected with P. aeruginosa. Cystic Fibrosis Foundation Therapeutics (CFFT) is supporting a trial in infants in Australia.

Sponsor

The program is fully funded through the Cystic Fibrosis Foundation and is being conducted within the Therapeutics Development Network.



Contact us about Azithromycin >